Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
Beryl A. Koblin(New York Blood Center), Chuen‐Yen Lau(National Institutes of Health), Barney S. Graham(National Institutes of Health), Paul Goepfert(University of Maryland, Baltimore), Olivier Defawe(Infectious Disease Research Institute), Cecilia Morgan(Fred Hutch Cancer Center), Georgia D. Tomaras(National Institutes of Health), Lilian Saavedra(Asociación para la Conservación de la Cuenca Amazónica), Martín Casapía(Asociación para la Conservación de la Cuenca Amazónica), Zhixue Maggie Wang(Fred Hutch Cancer Center), M. Juliana McElrath(Fred Hutch Cancer Center), Lindsey R. Baden(Brigham and Women's Hospital), David C. Montefiori(Duke University), Qin Li(Fujian Normal University)
Cited by 43
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k